Notice of Completion of Acquisition of the Company's Own Shares

Japan, December 20, 2006 --- Astellas Pharma Inc. (Headquarters: Tokyo; President and CEO: Masafumi Nogimori) announced today that it completed acquisition of its own shares in the market, which was resolved by its Board of Directors on October 4, 2006.

Particulars
1. Class of shares acquired: Common stock of the Company
2. Period of acquisition: From October 5, 2006 to December 19, 2006
3. Total number of shares acquired: 29,046,300 shares
4. Total value of acquisition: ¥ 149,999,577,000
5. Method of acquisition: Purchased on the Tokyo Stock Exchange and through ToSTNeT-2 (closing price transaction)

(Reference)
Resolution of the Board of Directors on October 4, 2006
1. Reasons for acquisition of its own shares: In order to improve capital efficiency and enhance returns to shareholders
2. Class of shares to be acquired: Common stock of the Company
3. Number of shares to be acquired: 30 million shares (maximum)
   (equivalent to 5.32% of a total of issued shares)
4. Aggregate amount of acquisition cost: ¥ 150 billion (maximum)

Contacts for inquiries or additional information
Astellas Pharma Inc.
Corporate Communications
Tel: +81-3-3244-3201   Fax: +81-3-5201-7473
http://www.astellas.com